Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations

被引:58
|
作者
Boettcher, Sebastian [1 ]
Ritgen, Matthias [1 ]
Buske, Sebastian [1 ]
Gesk, Stefan [2 ]
Klapper, Wolfram [3 ,4 ]
Hoster, Eva [5 ]
Hiddemann, Wolfgang [5 ]
Unterhalt, Michael [5 ]
Dreyling, Martin [5 ]
Siebert, Reiner [2 ]
Kneba, Michael [1 ]
Pott, Christiane [1 ]
机构
[1] Univ Schleswig Holstein, Dept Med 2, Kiel, Germany
[2] Univ Schleswig Holstein, Inst Human Genet, Kiel, Germany
[3] Univ Schleswig Holstein, Dept Haematopathol, Kiel, Germany
[4] Univ Schleswig Holstein, Lymph Node Registry Kiel, Kiel, Germany
[5] Univ Munich, Hosp Grosshadern, Dept Internal Med 3, Munich, Germany
关键词
mantle cell lymphoma; flow cytometry; PCR; staging; minimal residual disease;
D O I
10.3324/haematol.11267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The increasing application of multi-color flow cytometry assays for staging and follow-up in mantle cell lymphoma necessitates that the specificity and sensitivity of this technique are evaluated. Data from prospective clinical trials comparing the clinical applicability of flow cytometry to routine diagnostic methods and to polymerase chain reaction are currently lacking. Design and Methods We applied a standardized four-color flow cytometry assay to 281 prospectively collected peripheral blood and bone marrow samples from 98 patients with mantle cell lymphoma participating in a multi-center clinical trial and compared the results to those obtained with conventional clinical staging and consensus primer IGH-polymerase chain reaction. Results The maximum sensitivity of flow cytometry using light chain restriction in CD19'CD5' sub-populations was 8.0x10(-4) while flow cytometry that relied on immunophenotypic aberrations was less sensitive (2.4x10(-3)). Mantle cell lymphoma cells were detected in 87.3% of 110 pre-treatment samples from 84 patients by flow cytometry and in 94.5% by polymerase chain reaction. Eight out of 84 patients (9.5%) diagnosed clinically as having stage II or III disease showed peripheral blood or bone marrow involvement according to flow cytometry, thus documenting more advanced disease. At follow-up residual lymphoma cells were detected by flow cytometry and concordantly by polymerase chain reaction in 10/171 samples (5.8%); however, 31 follow-up samples (18.1%) were positive for minimal residual disease according only to polymerase chain reaction analysis. Conclusions The sensitivity of four-color flow cytometry is comparable to that of IGH-polymerase chain reaction at initial staging but is less sensitive at follow-up after immuno-chemotherapy. Both techniques are highly valuable methods for accurate initial staging.
引用
收藏
页码:551 / 559
页数:9
相关论文
共 14 条
  • [11] Comparison of prognostic significance between multiparameter flow cytometry and realtime quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic
    王欣玉
    ChinaMedicalAbstracts(InternalMedicine), 2021, 38 (02) : 119 - 119
  • [12] Bone Marrow Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Childhood T-Cell Lymphoblastic Lymphoma Stage III, Detected by Flow Cytometry (FC) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR)
    Stark, Batia
    Avigad, Smadar
    Luria, Drorit
    Manor, Sigal
    Reshef-Ronen, Tali
    Avrahami, Gali
    Yaniv, Isaac
    PEDIATRIC BLOOD & CANCER, 2009, 52 (01) : 20 - 25
  • [13] Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma:: The importance of analysis at diagnosis and significance of long-term follow-up
    Papajík, T
    Jedlicková, K
    Kriegová, E
    Jarosová, M
    Raida, L
    Faber, E
    Hubácek, J
    Vondráková, J
    Pikalová, Z
    Indrák, K
    NEOPLASMA, 2001, 48 (06) : 501 - 505
  • [14] Updated Follow-Up In The CLL2007FMP Trial Supports The Non Superiority Of The Association Fludarabine-Cyclophosphamide (FC) Plus Campath Compared To FC Plus Rituximab and Points Out The Importance Of Minimal Residual Disease, By 6-Color Flow Cytometry Technique, On Progression Free Survival
    Feugier, Pierre
    Letestu, Remi
    Chevret, Sylvie
    Aurran, Therese
    Mahe, Beatrice
    Cazin, Bruno
    Tournilhac, Olivier
    Maisonneuve, Herve
    Casasnovas, Olivier
    Delmer, Alain
    Leblond, Veronique
    Royer, Bruno
    Corront, Brigitte
    Delepine, Roselyne
    Vaudaux, Sandrine
    Van den Neste, Eric
    Bene, Marie C.
    Cymbalista, Florence
    Lepretre, Stephane
    BLOOD, 2013, 122 (21)